Hemodynamic Effects of Antiarrhythmic Drugs

Frumin, Howard; Behrens, Scott; Martyn, Robert; Goldberg, Monica V.; Rubenfire, Melvyn; Kerin, Nicholas Z.

doi:10.1002/j.1552-4604.1991.tb03674.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Aging and Disease‐related Changes That May Require A Pacemaker1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1994

1997

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drugs and Metabolic Disorders A wide variety of drugs, including but not limited to many cardiovascular and psychiatric agents, can induce bradycardia or cause conduction disturbances 12 . Careful review of a patient's drug regimen for non‐essential medications that could induce bradyarrhythmias or conduction disturbances is a critical step prior to any decision about implanting a permanent pacemaker.…”

Section: Aging and Disease‐related Changes That May Require A Pacemakermentioning

confidence: 99%

Permanent Cardiac Pacemakers in the Elderly

Bush

Finucane²

1994

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

Section: Aging and Disease‐related Changes That May Require A Pacemakermentioning

confidence: 99%

Permanent Cardiac Pacemakers in the Elderly

Bush

Finucane²

1994

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two‐Stage Pharmacokinetic Analysis

Vadiei¹,

Troy²,

Korth‐Bradley³

et al. 1997

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The disposition of amiodarone, an antiarrhythmic agent was evaluated after a single intravenous infusion (5 mg/kg over 15 minutes) in patients of various ages and with various degrees of renal function and left ventricular function. The plasma concentration-time data were obtained from three clinical studies with similar protocols. The data were analyzed by nonlinear mixed-effects modeling (NONMEM) to estimate the population pharmacokinetic parameters of amiodarone and to determine the significant demographic covariates affecting these parameters. The pharmacokinetic parameters of amiodarone (weight-corrected) also were calculated using two-stage analysis and were compared with the results obtained from the mixed-effects analysis. The population plasma concentration-time profile of amiodarone was best described by a four-compartment model. Demographic covariates (i.e., creatinine clearance and ejection fraction) did not improve the final pharmacostatistical model significantly. The results from the two-stage analysis showed no significant relationship between amiodarone pharmacokinetic parameters and age, gender, renal function, or ejection fraction. The results from one study, however, demonstrated that advanced age (> or = 65 years) resulted in reduced amiodarone clearance coupled with a prolonged elimination half-life. No such correlation was detected with NONMEM analysis, which may be partly attributable to the small number of elderly patients. Overall, the results from NONMEM analysis validated the results obtained from the two-stage analysis.

show abstract

Hemodynamic Effects of Antiarrhythmic Drugs

Cited by 2 publications

References 101 publications

Permanent Cardiac Pacemakers in the Elderly

Permanent Cardiac Pacemakers in the Elderly

Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two‐Stage Pharmacokinetic Analysis

Contact Info

Product

Resources

About